Sign Out
Use in Pregnancy: The safety of eletriptan in pregnant women has not been established. There is no evidence of teratogenicity in animal studies. Administration of RELPAX should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.
Use in Lactation: Eletriptan is excreted in human breast milk. In one study of 8 women given a single dose of 80 mg, the mean total amount of eletriptan in breast milk over 24 hours in this group was 0.02% of the dose. Nevertheless, caution should be exercised when considering the administration of RELPAX to women who are breast-feeding. Infant exposure can be minimised by avoiding breast-feeding for 24 hours after treatment.
Continue with Google